Iterum Therapeutics plc (ITRM)

Market Cap	40.40M
Revenue (ttm)	n/a
Net Income (ttm)	-22.56M
Shares Out	40.00M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	436,193
Open	0.976
Previous Close	0.980
Day's Range	0.976 - 1.050
52-Week Range	0.808 - 3.020
Beta	2.91
Analysts	Strong Buy
Price Target	7.00 (+593.07%)
Earnings Date	May 13, 2025

About ITRM

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 25, 2018
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: ITRM
• Website: https://www.iterumtx.com

Analyst Forecast

According to 2 analysts, the average rating for ITRM stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 593.07% from the latest price.

Price Target

$7.0

(593.07% upside)

Analyst Consensus: Strong Buy